Company & Sponsor Intelligence
MapLight Therapeutics
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting1
Completed0
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →